Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Avanir Pharmaceuticals Inc Announces Diabetes Co-Promotion Agreement with Merck & Co Inc


Monday, 12 Aug 2013 04:00pm EDT 

Avanir Pharmaceuticals Inc announced that it has entered into an exclusive, multi-year agreement with Merck & Co Inc known as MSD outside the United States and Canada, to co-promote Merck's type 2 diabetes therapies JANUVIA (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the United States. 

Company Quote

62.56
 --
27 Jan 2015